Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. Its Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products for photonics-based applications, such as industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The company's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless, recorder, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. Its Precision Motion segment offers optical and inductive encoders, precision motors, motion control sub-assemblies, servo drives, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: novanta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2026 | $144.00 | Neutral → Outperform | Robert W. Baird |
| 5/11/2022 | Mkt Perform → Outperform | William Blair |
Fastest customizable press release news feed in the world
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com. A replay of the audio webcast will be available approximately
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation
Novanta Inc. ("Novanta" or the "Company") announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares ("Common Shares") to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions. The offer and s
Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challen
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability t
First Quarter 2026 GAAP Revenue increased 10% to $258 million First Quarter 2026 GAAP Net Income was $21 million, and Adjusted EBITDA increased 14% to $57 million First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) April 3, March 28, 2026 2025
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 results after the close of U.S. financial markets on Monday, May 11, 2026. The Company will host a conference call on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hou
Novanta Inc. (NASDAQ:NOVT) announced today that it has joined NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited inspection lab for AI-driven physical systems. The lab helps accelerate certification and advance trust in key components and subsystems enabling the next generation of robotics and physical AI systems. By participating in Halos AI Systems Inspection Lab, Novanta will work with NVIDIA to validate the interoperability of our motion control and sensing technologies with safety requirements of NVIDIA platforms, including NVIDIA IGX Thor. This collaboration is designed to streamline the adoption of critical technology solutions to
Fourth Quarter 2025 GAAP Revenue increased 9% to $258 million, and GAAP Diluted EPS was $0.45 Fourth Quarter 2025 Adjusted Diluted EPS was $0.91, increased 20%, and Adjusted EBITDA was $61 million, increased 17% Full Year 2025 GAAP Revenue increased 3% to $981 million, and GAAP Diluted EPS was $1.47 Full Year 2025 Adjusted Diluted EPS was $3.29, and Adjusted EBITDA was $221 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31,
S-3ASR - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
SD - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
10-Q - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
DEF 14A - NOVANTA INC (0001076930) (Filer)
SCHEDULE 13G/A - NOVANTA INC (0001076930) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Robert W. Baird upgraded Novanta from Neutral to Outperform and set a new price target of $144.00
William Blair upgraded Novanta from Mkt Perform to Outperform
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
Live Leadership Updates
IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Live finance-specific insights
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com. A replay of the audio webcast will be available approximately
Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from
First Quarter 2026 GAAP Revenue increased 10% to $258 million First Quarter 2026 GAAP Net Income was $21 million, and Adjusted EBITDA increased 14% to $57 million First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) April 3, March 28, 2026 2025
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 results after the close of U.S. financial markets on Monday, May 11, 2026. The Company will host a conference call on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hou
Fourth Quarter 2025 GAAP Revenue increased 9% to $258 million, and GAAP Diluted EPS was $0.45 Fourth Quarter 2025 Adjusted Diluted EPS was $0.91, increased 20%, and Adjusted EBITDA was $61 million, increased 17% Full Year 2025 GAAP Revenue increased 3% to $981 million, and GAAP Diluted EPS was $1.47 Full Year 2025 Adjusted Diluted EPS was $3.29, and Adjusted EBITDA was $221 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31,
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The Company will host a conference call on Tuesday, February 24, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the
Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26, September 27, 2025 2024 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 results on Tuesday, November 4, 2025. The Company will host a conference call on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the ca
Second Quarter 2025 GAAP Revenue increased 2% to $241 million Second Quarter 2025 GAAP Net Income of $4.5 million Second Quarter 2025 GAAP Diluted Earnings Per Share of $0.12 Second Quarter 2025 Adjusted EBITDA of $52 million Second Quarter 2025 Adjusted EPS of $0.76 Company updates Full Year 2025 financial guidance Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) June 27, June 28,
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2025 results on Tuesday, August 5, 2025. The Company will host a conference call on Tuesday, August 5, 2025, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call
This live feed shows all institutional transactions in real time.
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)